P. Cramer Et Al. , "Systemic Exposure of Rituximab Increased By Ibrutinib: Pharmacokinetic Results from the Helios Trial," 58th Annual Meeting and Exposition of the American-Society-of-Hematology , vol.128, California, United States Of America, 2016
Cramer, P. Et Al. 2016. Systemic Exposure of Rituximab Increased By Ibrutinib: Pharmacokinetic Results from the Helios Trial. 58th Annual Meeting and Exposition of the American-Society-of-Hematology , (California, United States Of America).
Cramer, P., DEMİRKAN, F., Fraser, G., Pristupa, A., Bartlett, N. L., Dilhuydy, M., ... Loscertales, J.(2016). Systemic Exposure of Rituximab Increased By Ibrutinib: Pharmacokinetic Results from the Helios Trial . 58th Annual Meeting and Exposition of the American-Society-of-Hematology, California, United States Of America
Cramer, Paula Et Al. "Systemic Exposure of Rituximab Increased By Ibrutinib: Pharmacokinetic Results from the Helios Trial," 58th Annual Meeting and Exposition of the American-Society-of-Hematology, California, United States Of America, 2016
Cramer, Paula Et Al. "Systemic Exposure of Rituximab Increased By Ibrutinib: Pharmacokinetic Results from the Helios Trial." 58th Annual Meeting and Exposition of the American-Society-of-Hematology , California, United States Of America, 2016
Cramer, P. Et Al. (2016) . "Systemic Exposure of Rituximab Increased By Ibrutinib: Pharmacokinetic Results from the Helios Trial." 58th Annual Meeting and Exposition of the American-Society-of-Hematology , California, United States Of America.
@conferencepaper{conferencepaper, author={Paula Cramer Et Al. }, title={Systemic Exposure of Rituximab Increased By Ibrutinib: Pharmacokinetic Results from the Helios Trial}, congress name={58th Annual Meeting and Exposition of the American-Society-of-Hematology}, city={California}, country={United States Of America}, year={2016}}